Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Nov 7, 2016; 22(41): 9186-9195
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9186
Table 1 Characteristics of hepatitis B e antigen-negative chronic hepatitis B children
Characteristic
n52
Age (yr)
Median (range)16 (4-18)
Gender
Female/male16 (30.8)/36 (69.2)
Staging (F)
F0/F1/F2/F32 (3.9)/31 (59.6)/16 (30.7)/3 (5.8)
Grading (A)
A0/A1/A22 (3.9)/ 22 (42.3)/28 (53.8)
IL28B SNPs
rs12979860 CC/CT/TT20 (38.5)/26 (50.0)/6 (11.5)
rs12980275 AA/AG/GG24 (46.2)/24 (46.2)/4 (7.6)
rs8099917 TT/TG/GG30 (57.7)/19 (36.5)/3 (5.8)
OAS SNPs
rs10849829 AA/AG/GG19 (36.5)/27 (52.0)/6 (11.5)
rs1131476 AA/AG/GG26 (50.0)/17 (32.7)/9 (17.3)
rs1293747 GG/GA/AA32 (61.5)/17 (32.7)/3 (5.8)
rs2072136 GG/GA/AA30 (57.7)/20 (38.5)/2 (3.8)
Baseline HBV DNA (IU/mL)
median (range), log4.6 (3.4-8.0)
< 2000031 (59.6)
Baseline ALT (U/L)
median (range)42 (12-210)
< 4014 (26.9)
At week 24 of treatment
HBV DNA < 100 (IU/mL)32 (61.5)
ALT < 40 (U/L)13 (25.0)
At the end of treatment
HBV DNA < 2000 (IU/mL)39 (75.0)
ALT < 40 (U/L)28 (53.9)
24 wk post-treatment
HBV DNA < 2000 (IU/mL)27 (51.92)
ALT < 40 (U/L)37 (71.15)
Partial response
< 2000 IU/mL HBV DNA or < 40 IU/L ALT42 (80.8)
Complete response
< 2000 IU/mL HBV DNA with < 40 IU/L ALT22 (42.3)
Table 2 Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children
CharacteristicPR,No-PR,P valueOR (95%CI)
n = 42n = 10
Age (yr)
Median (range)16 (4-18)16 (5-18)0.803
Gender
Female14 (33.3)2 (20.0)0.412
Staging (F)
F0-F126 (61.9)7 (70.0)0.729
Grading (A)
A0-A120 (47.6)5 (50.0)0.892
Baseline HBV DNA (IU/mL)
Median (range), log4.1 (3.4-8.0)5.9 (3.6-8.0)0.017
< 2000028 (66.7)3 (30.0)0.069
Baseline ALT (U/L)
Median (range)44 (10-120)63 (22-118)0.003
< 4013 (31.0)1 (10.0)0.207
IL28B rs12979860
CC19 (45.2)1 (10.0)0.068
CT20 (47.6)6 (60.0)
TT3 (7.2)3 (30.0)0.077
IL28B rs12980275
AA23 (54.8)1 (10.0)0.01410.9 (1.3-93.9)
AG17 (40.6)7 (70.0)
GG2 (4.8)2 (20.0)0.163
IL28B rs8099917
TT27 (64.2)3 (30.0)0.075
TG13 (31.0)6 (60.0)
GG2 (4.8)1 (10.0)0.481
OASL rs10849829
AA16 (38.1)5 (50.0)0.500
AG20 (47.6)5 (50.0)
GG6 (14.3)0 (0.0)0.582
OAS1 rs1131476
AA19 (45.2)7 (70.0)0.291
AG15 (35.7)2 (20.0)
GG8 (19.1)1 (10.0)0.670
OAS2 rs1293747
GG25 (59.5)7 (70.0)0.481
GA15 (35.7)2 (20.0)
AA2 (4.8)1 (10.0)0.722
OAS3 rs2072136
GG23 (54.8)7 (70.0)1.000
GA17 (40.6)3 (30.0)
AA2 (4.8)0 (0.0)0.488
Table 3 Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children
CharacteristicCR,No-CR,P valueOR (95%CI)
n = 22n = 30
Age (yr)
Median (range)16 (12-18)17 (4-18)0.141
Gender
Female8 (36.4)8 (26.7)0.454
Staging (F)
F0-F114 (63.6)19 (63.3)0.942
Grading (A)
A0-A110 (45.5)15 (50.0)0.746
Baseline HBV DNA (IU/mL)
Median (range), log4.6 (3.4-8.0)4.7 (3.5-8.0)0.671
< 2000014 (63.6)17 (56.7)0.613
Baseline ALT (U/L)
Median (range)43 (10-110)48 (17-126)0.116
< 408 (36.3)6 (20.0)0.189
IL28B rs12979860
CC8 (36.4)12 (40.0)0.790
CT14 (63.6)12 (40.0)
TT0 (0.0)6 (20.0)0.033NA
IL28B rs12980275
AA11 (50.0)13 (43.3)0.634
AG11 (50.0)13 (43.3)
GG0 (0.0)4 (13.4)0.128
IL28B rs8099917
TT15 (68.2)15 (50.0)0.190
TG7 (31.8)12 (40.0)
GG0 (0.0)3 (10.0)0.253
OASL rs10849829
AA5 (22.7)16 (53.3)0.0260.26 (0.07-0.88)
AG14 (63.6)11 (36.7)
GG3 (13.6)3 (10.0)0.685
OAS1 rs1131476
AA10 (45.5)16 (53.3)0.575
AG8 (36.4)9 (30.0)
GG4 (18.1)5 (16.7)0.887
OAS2 rs1293747
GG14 (63.6)18 (60.0)0.253
GA8 (36.4)9 (30.0)
AA0 (0.0)3 (10.0)0.790
OAS3 rs2072136
GG15 (68.2)15 (50.0)1.000
GA6 (27.3)14 (46.7)
AA1 (4.5)1 (3.3)0.190
Table 4 Association of OAS haplotypes with treatment response
HaplotypeCRNo-CRP valueOR (95%CI)PRNo-PRP valueOR (95%CI)
A A A A0.110.160.4020.60 (0.18-1.98)0.160.000.041NA
A A G A0.030.050.4730.47 (0.06-3.78)0.050.000.283NA
A A G G0.170.350.0310.35 (0.13-0.92)0.210.570.0020.21 (0.07-0.61)
A G G G0.240.120.1562.11 (0.74-6.00)0.170.130.5431.55 (0.37-6.48)
G A G G0.280.030.000311.96 (2.38-59.97)0.160.050.1733.91 (0.48-31.8)
G G G G0.050.170.0460.24 (0.05-1.06)0.150.050.1943.70 (0.45-30.25)